Somatic mutations rather than viral infection classify focal cortical dysplasia type II as mTORopathy

Current Opinion in Neurology

Volumn 29, Issue 3, 2016, Pages 388-395

  Blümcke, Ingmar ^a,b   Sarnat, Harvey B ^c,d  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Department of Paediatrics ^*  (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

brain; cortical dysplasia; mammalian target of rapamycin; neocortex; neuroembryology; neuropathology

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN E6; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ALEXANDER DISEASE; BRAIN CORTEX; BRAIN MALFORMATION; BRAIN VENTRICLE; CELL CYCLE; CELL MATURATION; CELL MIGRATION; CORTICAL DYSPLASIA; CYTOMEGALY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; EPILEPSY; FOCAL CORTICAL DYSPLASIA TYPE II; GRAY MATTER; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MOSAICISM; NERVE CELL DIFFERENTIATION; NERVE CELL NETWORK; NEUROEPITHELIUM CELL; NEUROPATHOLOGY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PERSONALIZED MEDICINE; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; WHITE MATTER; CELL PROLIFERATION; COMPLICATION; GENETICS; MALFORMATION OF CORTICAL DEVELOPMENT GROUP I; MUTATION; VIROLOGY;

CELL PROLIFERATION; EPILEPSY; HUMANS; MALFORMATIONS OF CORTICAL DEVELOPMENT, GROUP I; MUTATION; PAPILLOMAVIRUS INFECTIONS; TOR SERINE-THREONINE KINASES;

EID: 84956902076     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000303     Document Type: Review

References (62)

1. Blumcke I, Russo GL, Najm I, Palmini A. Pathology-based approach to epilepsy surgery. Acta Neuropathol 2014; 128:1-3. [Epub ahead of print]
2. Blümcke I, Sarnat HB, Coras R. Surgical neuropathology of focal epilepsies: textbook and atlas. Montrouge, France: John Libbey Eurotext; 2015.
3. Steinlein OK, Mulley JC, Propping P, et al. A missence mutation in the neuronal nicotinic acetylcholine receptor a4 subunit is associated with auto-somal dominant nocturnal frontal lobe epilepsy. Nat Gen 1995; 11:201-203.
4. Lerner JT, Salamon N, Hauptman JS, et al. Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia 2009; 50:1310-1335; Epub 2009/01/30.
5. Blumcke I, Thom M, Aronica E, et al. The clinico-pathological spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011; 52:158-174.
6. Guerrini R, Duchowny M, Jayakar P, et al. Diagnostic methods and treatment options for focal cortical dysplasia. Epilepsia 2015; 56:1669-1686. [Epub ahead of print]
7. Palmini A, Najm I, Avanzini G, et al. Terminology and classification of the cortical dysplasias. Neurology 2004; 62 (6 Suppl 3):S2-S8.
8. Najm IM, Tassi L, Sarnat HB, et al. Epilepsies associated with focal cortical dysplasias (FCDs). Acta Neuropathol 2014; 128:5-19. [Epub head of print]
9. Harvey AS, Mandelstam SA, Maixner WJ, et al. The surgically remediable syndrome of epilepsy associated with bottom-of-sulcus dysplasia. Neurology 2015; 84:2021-2028. [Epub ahead of print]
10. Besson P, Andermann F, Dubeau F, Bernasconi A. Small focal cortical dysplasia lesions are located at the bottom of a deep sulcus. Brain: J Neurol 2008; 131 (Pt 12):3246-3255; Epub 2008/09/25.
11. Zucca I, Milesi G, Medici V, et al. Type II FCD: ex vivo 7 Tesla MRI abnormalities and histopathological comparisons. Ann Neurol 2015; doi: 101002/ana24541 [Epub ahead of print]
12. Fauser S, Essang C, Altenmuller DM, et al. Long-term seizure outcome in 211 patients with focal cortical dysplasia. Epilepsia 2015; 56:66-76. [Epub ahead of print]
13. Muhlebner A, Groppel G, Dressler A, et al. Epilepsy surgery in children and adolescents with malformations of cortical development-outcome and impact of the new ILAE classification on focal cortical dysplasia. Epilepsy Res 2014; 108:1652-1661. [Epub ahead of print]
14. Becker AJ, Urbach H, Scheffler B, et al. Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. Ann Neurol 2002; 52:29-37.
15. Dibbens LM, de Vries B, Donatello S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013; 45:546-551. [Epub ahead of print]
16. Ishida S, Picard F, Rudolf G, et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet 2013; 45:552-555. [Epub ahead of print]
17. Bar-Peled L, Chantranupong L, Cherniack AD, et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013; 340:1100-1106.
18. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801-1811. [Epub ahead of print]
19. Lal D, Reinthaler EM, Schubert J, et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol 2014; 75:788-792. [Epub ahead of print]
20. Scheffer IE, Heron SE, Regan BM, et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol 2014; 75:782-787. [Epub ahead of print]
21. Baulac S, Ishida S, Marsan E, et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations. Ann Neurol 2015; 77:675-683.
22. Scerri T, Riseley JR, Gillies G, et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann Clin Transl Neurol 2015; 2:575-580. [Epub ahead of print]
23. Picard F, Makrythanasis P, Navarro V, et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology 2014; 82:2101-2106. [Epub ahead of print]
24. D'Gama AM, Geng Y, Couto JA, et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol 2015; 77:720-725.
25. Jamuar SS, Lam AT, Kircher M, et al. Somatic mutations in cerebral cortical malformations. N Engl J Med 2014; 371:733-743. [Epub ahead of print]
26. Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med 2015; 21:395-400. [Epub ahead of print]
27. Nakashima M, Saitsu H, Takei N, et al. Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann Neurol 2015; 78:375-386. [Epub ahead of print]
28. Leventer RJ, Scerri T, Marsh AP, et al. Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR. Neurology 2015; 84:2029-2032. [Epub ahead of print]
29. Jansen LA, Mirzaa GM, Ishak GE, et al. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. Brain 2015; 138 (Pt 6):1613-1628. [Epub ahead of print]
30. Lin YX, Lin K, Liu XX, et al. PI3K-AKT pathway polymerase chain reaction (PCR) array analysis of epilepsy induced by type II focal cortical dysplasia. Genet Mol Res 2015; 14:9994-10000.
31. Sim JC, Scerri T, Fanjul-Fernandez M, et al. Familial cortical dysplasia caused by mutation in the mTOR regulator NPRL3. Ann Neurol 2015; doi: 10.1002/ana24541. [Epub ahead of print]
32. Lee JH, Huynh M, Silhavy JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012; 44:941-945. [Epub ahead of print]
33. Evrony GD, Cai X, Lee E, et al. Single-neuron sequencing analysis of L1 retrotransposition and somatic mutation in the human brain. Cell 2012; 151:483-496. [Epub ahead of print]
34. Spangle JM, Munger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol 2010; 84:9398-9407. [Epub ahead of print]
35. Chen J, Tsai V, Parker WE, et al. Detection of human papillomavirus in human focal cortical dysplasia type IIB. Ann Neurol 2012; 72:881-892. [Epub ahead of print]
36. Liu S, Lu L, Cheng X, et al. Viral infection and focal cortical dysplasia. Ann Neurol 2013; 75:614-616. [Epub ahead of print]
37. Thom M, Liu J, Reeves C, et al. A cautionary note in the interpretation of human papillomavirus E6 immunohistochemistry in focal cortical dysplasia. Ann Neurol 2015; 77:352-353. [Epub ahead of print]
38. Shapiro KA, McGuone D, Deshpande V, et al. Failure to detect human papillomavirus in focal cortical dysplasia type IIb. Ann Neurol 2015; 78:63-67.
39. Coras R, Korn K, Bien CG, et al. No evidence for human papillomavirus infection in focal cortical dysplasia IIb. Ann Neurol 2015; 77:312-319. [Epub ahead of print]
40. Fauser S, Haussler U, Donkels C, et al. Disorganization of neocortical lamination in focal cortical dysplasia is brain-region dependent: evidence from layer-specific marker expression. Acta Neuropathol Commun 2013; 1:47. [Epub ahead of print]
41. Hadjivassiliou G, Martinian L, Squier W, et al. The application of cortical layer markers in the evaluation of cortical dysplasias in epilepsy. Acta Neuropathol 2010; 120:517-528. [Epub ahead of print]
42. Sakakibara T, Sukigara S, Saito T, et al. Delayed maturation and differentiation of neurons in focal cortical dysplasia with the transmantle sign: analysis of layer-specific marker expression. J Neuropathol Exp Neurol 2012; 71:741-749. [Epub ahead of print]
43. Arai A, Saito T, Hanai S, et al. Abnormal maturation and differentiation of neocortical neurons in epileptogenic cortical malformation: unique distribution of layer-specific marker cells of focal cortical dysplasia and hemimega-lencephaly. Brain Res 2012; 1470:89-97. [Epub ahead of print]
44. Sarnat HB. Immunocytochemical markers of neuronal maturation in human diagnostic neuropathology. Cell Tissue Res 2015; 359:279-294.
45. Sarnat HB, Philippart M, Flores-Sarnat L, Wei XC. Timing in neural develop-ment: arrest, delay, precociousness, and temporal determination of malformations. Pediat Neurol 2015; 52:473-486.
46. Caviness VS Jr, Pinto-Lord MC, Evrand P. The development of laminated patterns in the mammalian neocortex. Connely TG, editor. New York: Raven Press; 1981.
47. Hildebrandt M, Pieper T, Winkler P, et al. Neuropathological spectrum of cortical dysplasia in children with severe focal epilepsies. Acta Neuropathol 2005; 110:1-11.
48. Blumcke I, Pieper T, Pauli E, et al. A distinct variant of focal cortical dysplasia type I characterised by magnetic resonance imaging and neuropathological examination in children with severe epilepsies. Epileptic Disord 2010; 12:172-180. [Epub ahead of print]
49. Krsek P, Pieper T, Karlmeier A, et al. Different presurgical characteristics and seizure outcomes in children with focal cortical dysplasia type I or II. Epilepsia 2009; 50:125-137. [Epub ahead of print]
50. Sarnat HB, Flores-Sarnat L. Radial microcolumnar cortical architecture: maturational arrest or cortical dysplasia? Pediatr Neurol 2013; 48:259-270. [Epub ahead of print]
51. Sarnat HB. Clinical neuropathology practice guide 5-2013: markers of neuronal maturation. Clin Neuropathol 2013; 32:340-369. [Epub ahead of print]
52. Liu J, Reeves C, Michalak Z, et al. Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies. Acta Neuropathol Commun 2014; 2:71.
53. LaSarge CL, Danzer SC. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front Mol Neurosci 2014; 7:18.
54. Cloetta D, Thomanetz V, Baranek C, et al. Inactivation of mTORC1 in the developing brain causes microcephaly and affects gliogenesis. J Neurosci 2013; 33:7799-7810.
55. Thomanetz V, Angliker N, Cloetta D, et al. Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology. J Cell Biol 2013; 201:293-308.
56. Pun RY, Rolle IJ, Lasarge CL, et al. Excessive activation of mTOR in post-natally generated granule cells is sufficient to cause epilepsy. Neuron 2012; 75:1022-1034.
57. Huang W, Zhu PJ, Zhang S, et al. mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat Neurosci 2013; 16:441-448.
58. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74:679-687.
59. Nguyen LH, Brewster AL, Clark ME, et al. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia. Epilepsia 2015; 56:636-646.
60. Cardamone M, Flanagan D, Mowat D, et al. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr 2014; 164:1195-1200.
61. Tillema JM, Leach JL, Krueger DA, Franz DN. Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology 2012; 78:526-531. [Epub ahead of print]
62. Sarnat H, Flores-Sarnat L, Crino P, et al. Hemimegalencephaly: foetal tauo-pathy with mTOR hyperactivation and neuronal lipidosis. Folia Neuropathol 2012; 50:330-345. [Epub ahead of print]